69 related articles for article (PubMed ID: 29644640)
1. CHAPTER 7 Methods for detection of HPV infection and its clinical utility.
Villa LL; Denny L
Int J Gynaecol Obstet; 2006 Nov; 94 Suppl 1():S71-S80. PubMed ID: 29644640
[TBL] [Abstract][Full Text] [Related]
2. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
3. The clinical utility of HPV DNA testing in cervical cancer screening strategies.
Bhatla N; Moda N
Indian J Med Res; 2009 Sep; 130(3):261-5. PubMed ID: 19901435
[TBL] [Abstract][Full Text] [Related]
4. The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies.
Poljak M; Oštrbenk A
Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(2):43-7. PubMed ID: 23836358
[TBL] [Abstract][Full Text] [Related]
5. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
[TBL] [Abstract][Full Text] [Related]
6. Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas® HPV Test results from the ATHENA study.
Rao A; Sandri MT; Sideri M; Young S; Sharma A; Behrens C
J Clin Virol; 2013 Sep; 58(1):161-7. PubMed ID: 23895930
[TBL] [Abstract][Full Text] [Related]
7. Validation of ThermoFisher's Papspin for human papillomavirus detection in cervicovaginal specimens using PCR with GP5+/GP6+ primers and the Hybrid Capture II assay.
Weynand B; Delvenne P; Polet R; Guiot Y; Arafa M; Somja J; Galant C
Clin Microbiol Infect; 2010 Jun; 16(6):671-5. PubMed ID: 19689463
[TBL] [Abstract][Full Text] [Related]
8. Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing.
Sherman ME; Schiffman MH; Lorincz AT; Herrero R; Hutchinson ML; Bratti C; Zahniser D; Morales J; Hildesheim A; Helgesen K; Kelly D; Alfaro M; Mena F; Balmaceda I; Mango L; Greenberg M
Cancer; 1997 Apr; 81(2):89-97. PubMed ID: 9126136
[TBL] [Abstract][Full Text] [Related]
9. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types.
Castle PE; Schiffman M; Burk RD; Wacholder S; Hildesheim A; Herrero R; Bratti MC; Sherman ME; Lorincz A
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1394-9. PubMed ID: 12433717
[TBL] [Abstract][Full Text] [Related]
10. Comparison of fluorescence in situ hybridization, hybrid capture 2 and polymerase chain reaction for the detection of high-risk human papillomavirus in cervical cytology specimens.
Voss JS; Kipp BR; Campion MB; Sokolova IA; Henry MR; Halling KC; Clayton AC
Anal Quant Cytol Histol; 2009 Aug; 31(4):208-16. PubMed ID: 19736868
[TBL] [Abstract][Full Text] [Related]
11. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.
Arbyn M; Sasieni P; Meijer CJ; Clavel C; Koliopoulos G; Dillner J
Vaccine; 2006 Aug; 24 Suppl 3():S3/78-89. PubMed ID: 16950021
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a multiplex real time PCR assay for the detection of human papillomavirus infections on self-collected cervicovaginal lavage samples.
Jentschke M; Soergel P; Hillemanns P
J Virol Methods; 2013 Oct; 193(1):131-4. PubMed ID: 23707925
[TBL] [Abstract][Full Text] [Related]
13. Aptima HPV Assay versus Hybrid Capture
Cook DA; Smith LW; Law J; Mei W; van Niekerk DJ; Ceballos K; Gondara L; Franco EL; Coldman AJ; Ogilvie GS; Jang D; Chernesky M; Krajden M
J Clin Virol; 2017 Feb; 87():23-29. PubMed ID: 27988420
[TBL] [Abstract][Full Text] [Related]
14. High-risk HPV DNA testing and HPV-16/18 genotyping: what is the clinical application?
Twiggs LB; Hopkins M
J Low Genit Tract Dis; 2011 Jul; 15(3):224-30. PubMed ID: 21716051
[TBL] [Abstract][Full Text] [Related]
15. Retrospective and prospective evaluation of the Amplicor HPV test for detection of 13 high-risk human papillomavirus genotypes on 862 clinical samples.
Poljak M; Fujs K; Seme K; Kocjan BJ; Vrtacnik-Bokal E
Acta Dermatovenerol Alp Pannonica Adriat; 2005 Dec; 14(4):147-52. PubMed ID: 16435043
[TBL] [Abstract][Full Text] [Related]
16. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus.
Dalstein V; Merlin S; Bali C; Saunier M; Dachez R; Ronsin C
J Virol Methods; 2009 Mar; 156(1-2):77-83. PubMed ID: 19041893
[TBL] [Abstract][Full Text] [Related]
17. Resolving repeatedly borderline results of Hybrid Capture 2 HPV DNA Test using polymerase chain reaction and genotyping.
Seme K; Fujs K; Kocjan BJ; Poljak M
J Virol Methods; 2006 Jun; 134(1-2):252-6. PubMed ID: 16417931
[TBL] [Abstract][Full Text] [Related]
18. An HPV 16, 18, and 45 genotyping test based on Hybrid Capture technology.
Thai H; Rangwala S; Gay T; Keating K; McLeod S; Nazarenko I; O'Neil D; Pfister D; Loeffert D
J Clin Virol; 2009 Jul; 45 Suppl 1():S93-7. PubMed ID: 19651375
[TBL] [Abstract][Full Text] [Related]
19. High performance of combined HPV testing and genotyping for HPV16/18/52/58 in triaging women with minor cervical cytological abnormalities in northern Thailand.
Khunamornpong S; Settakorn J; Sukpan K; Srisomboon J; Intaraphet S; Siriaunkgul S
J Med Virol; 2016 Jan; 88(1):135-43. PubMed ID: 26129775
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
